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Neonatal seizures (NS) are the most frequent clinical manifestation of the central nervous system dysfunction in the newborn. Its prevalence is approximately 1.5%, and 
overall incidence approximately 3/1000 live births. The incidence 
of pre-term infants is very high (57–132/1000 live births). Most 
(80%) of the NSs occur in the first 1–2 days to the 1st week of 
life [1]. NS have deleterious effects on the developing brain, so 
their prompt recognition and treatment are crucial to prevent 
future complications. The most common causes of seizures 
in the neonatal period are hypoxic-ischemic encephalopathy 
(HIE), central nervous system infections, cerebral infarctions, 
intracranial hemorrhage, and metabolic abnormalities.
There are currently no evidence-based guidelines for the 
evaluation and management of NS. Phenobarbitone (PB) is 
considered as the first-line treatment for NS [2]. Yet, a recent 
Cochrane review concluded that there was little evidence 
from randomized controlled trials to support the use of any of 
the anticonvulsants currently used in the neonatal period [3]. 
Conventional treatment (PB and phenytoin) only achieves 
clinical control in 50–80% of cases and is even less effective in 
controlling most neonatal electroencephalographic seizures [4]. 
However, there is increasing concern over the long-term adverse 
effects of PB, since it was shown to increase neuronal apoptosis 
in animal models [5] and induces cognitive impairment in infants 
and toddlers [6].
Levetiracetam (LEV) is an effective and well-tolerated 
antiepileptic drug currently licensed for the treatment of NS. 
There are hardly any reports of severe, life-threatening side 
effects, while most frequently observed adverse effects included 
somnolence and behavioral problems [7]. Furthermore, LEV 
presents a favorable profile regarding neuronal apoptosis: In 
contrast to most other established anti-epileptic drugs, it was not 
found to increase apoptosis in the developing rodent brain [8] and 
does not interfere with neuroprotective upregulation of hypoxia-
inducible factor 1 [9] and decreases neurodegeneration in rodent 
models of hypoxia/ischemia [10] or epilepsy [11,12]. This study 
was done to compare efficacy of LEV and PB in the treatment of 
clinically apparent seizures in term neonates and their outcome on 
follow-up at 1 year of age.
MATERIALS AND METHODS
This was an open-label randomized controlled study. This 
study included 80 neonates (57 males and 23 females) admitted 
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in neonatal intensive care unit (NICU) of the department of 
pediatrics of a tertiary hospital in Bihar suffering from clinically 
apparent seizure during the period from April 2018 to September 
2019. The present study was conducted in accordance with the 
current version of the Declaration of Helsinki. Informed written 
consents were taken from guardian/parents of children involved.
Block randomization of 80 numbers in blocks of four was 
done using computer generated random numbers. They were put 
in serially numbered opaque envelopes and sealed. This was done 
by a person not involved in study. These pre-numbered sealed 
envelopes were opened to determine the anticonvulsant to be 
given to the baby. Our trial was an open-label trial, so the doctors 
and nursing staff were aware of the treatment assignments. 
However, the electroencephalography (EEG) technicians and 
neurologist reporting the EEG were blinded to the intervention.
The inclusion criteria were all term neonates (≥37 weeks of 
gestation) admitted with clinically apparent seizures after ruling 
out hypoglycemia, hypocalcemia, and other metabolic disorders. 
Clinical criteria for the diagnosis of NS were subtle seizures 
and spontaneous paroxysmal, repetitive motor or autonomic 
phenomena such as lip-smacking, chewing, paddling, cyclic 
movements, or respiratory irregularities. Neonates with clonic 
movement, which could be unifocal, multifocal or generalized, 
and tonic posturing with or without abnormal gaze were included 
in the study. The exclusion criteria were neonates with seizure 
responding to correction of hypoglycemia, hypocalcemia, or any 
other metabolic disorder. Preterm neonates (≤36 weeks 6 days of 
gestation), neonates with the major congenital malformation or 
myoclonic jerks, and neonates who were intubated at admission 
to NICU were also excluded from the study.
Patient details (name, age, sex, weight, head circumference, 
and length) were recorded on a pre-structured pro forma. Patency 
of airway, breathing, and circulation was ensured based on standard 
guidelines [13]. After a cannula was secured, blood sugar, serum 
calcium, and blood for other tests were drawn. Hypoglycemia was 
defined as blood sugar <45 mg/dl [13]. Hypocalcemia was defined 
as ionized calcium <4.8 mg/dl (1.2 mmol/l) in term neonates [14]. 
If seizures persisted even after correction of hypoglycemia and 
hypocalcemia, babies were randomized to either LEV (Group A) 
or PB (Group B).
In Group A, baby was loaded with initial intravenous (IV) doses 
of 10 mg/kg LEV. If seizures persisted, an additional aliquot of 
5 mg/kg was given to a total of 15 mg/kg of LEV. The maintenance 
therapy was continued every 12 h at the dose at which seizures were 
controlled. Cardiac rate, rhythm, and blood pressure were monitored 
during the infusion. If seizure persisted, the babies were crossed 
over to IV PB. In Group B, babies were loaded with injection PB 
at 20 mg/kg slow IV infusion over 30 min under cardiorespiratory 
monitoring. If seizure persisted, baby was reloaded with 10 mg/kg 
aliquots each to a maximum total dose of 40 mg/kg. The maintenance 
therapy was started after 24 h of loading of PB. If seizures persisted, 
baby was crossed over to receive IV LEV.
If seizure persisted after two drugs, and then a third-line 
drug-like midazolam was used IV at 0.2 mg/kg/dose followed by 
continuous infusion. Administration of the drug was discontinued 
if respiratory depression (cessation of respiration for >20 s, or 
<20 s associated with cyanosis or bradycardia), hypotension 
(mean blood pressure <35 mm-Hg), or bradycardia (heart rate 
<60/min) developed after use of either of the drugs. Once the 
baby was seizure-free for 5 days, anticonvulsants were stopped in 
the same order as they were started, and maintenance therapy was 
continued with the drug to which the case belonged.
IV PB and LEV were changed to oral once the baby was 
on 50% of enteral feeds. PB and LEV in respective group were 
stopped last at discharge if neurological examination was normal, 
and EEG demonstrated no electrical seizures. If neurological 
examination or EEG was abnormal or not done, then the drugs 
were continued after discharge, and baby was re-evaluated 
at the age of 3, 6, and 12 months for anticonvulsant efficacy, 
neurodevelopmental outcome, and other complications.
The primary outcome variable was cessation of clinical seizure 
activity (no seizure for 5 days). Secondary outcome variables 
were time taken to control seizures, survival at discharge, short-
term adverse effect and long-term neurodevelopmental outcome 
at 12 months (Amiel-Tison method), and EEG control of seizures.
A neurological examination was done in all babies at discharge. 
It included an examination of overall activity, response to stimuli, 
ability to suck and swallow, active and passive tone of neck and 
trunk muscles and neonatal reflexes. Examination at 3, 6, and 
12 months was done by examination of muscle tone by Amiel-
Tison method (adductor angle, popliteal angle, dorsiflexion angle, 
and scarf sign) and evaluation of developmental retardation by 
Pathak adaptation of Bayley scale. Achievement of milestones 
such as social smile, recognition of mother, neonatal reflexes 
(Moro’s reflex and grasp reflex), head circumference, and 
persistence of seizure was evaluated.
For those babies who could not come for follow-up, telephonic 
interviews of parents and local practitioners were conducted. 
They were asked about age, specific developmental milestones, 
weight gain, feeding, persistence of seizures, and overall 
perception of parents about neurological status and development. 
The neuromotor outcome was considered abnormal if tone of 
baby was outside of Amiel-Tison score range. Mental retardation 
was considered when Pathak adaptation of Bayley Scale came out 
to be abnormal.
Statistical analysis was done using intention to treat analysis. 
Results were analyzed using SPSS 23 software. Continuous data 
with normal distribution were analyzed by student t-test and non-
normally distributed data by Mann–Whitney test. Categorical 
data were analyzed by Chi-square test or Fischer exact test, where 
applicable. Statistical data were expressed in mean and standard 
deviation. p<0.05 was considered significant.
RESULTS
Out of 80 neonates who were screened, 42 babies were 
randomized to LEV group and 38 babies were randomized to PB 
group. Baseline characteristics and seizures characteristics were 
comparable in both groups (Table 1). In case of multiple types of 
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seizures in a baby, he was classified on the basis of first seizure 
type only.
Cessation of clinical seizure was observed in 28 of the 
42 (66.6%) neonates who received LEV and 31 of 38 (81.5%) 
neonates receiving PB first (p>0.05). After the maximum dose 
of PB, seizures were controlled in 32/38 (84.2%) in PB (p>0.05). 
Babies in whom seizure control were not achieved with first drug, 
after cross-over, seizure control was achieved in 40/42 (95.2%) of 
the neonates assigned to receive LEV first and 37/38 (97.3%) of 
those assigned to receive PB first (p>0.05).
Median (range) time taken to control all seizures was 
30 min (10 min–48 h) in HIE Stage II, 60 min (10 min–6 d) in 
HIE Stage III, 52 min (15 min–24 h) in meningitis, and 11 h 
(30 min–3 h) in intracranial hemorrhage. There was no significant 
difference in seizure control in the two groups (p>0.05). Short-
term adverse effects (cardiorespiratory depression and sedation) 
were noted in 3/42 babies in LEV group in comparison to 20/38 
babies in PB group (p<0.05).
A total of 18 babies expired during NICU stay (ten babies in 
PB group and eight babies in LEV group, p>0.05), and 62 were 
discharged. Twelve of these 18 deaths were in babies with HIE 
Stage III. Of the remaining, four were in HIE Stage II, 1 had sepsis 
and 1 had intra-ventricular hemorrhage. None of these mortalities 
were within 4 h of giving drugs so likely to be unrelated to drugs 
used, but due to underlying condition.
Among 62 discharged babies, 14 were lost to follow-up, and 
48 babies (25 babies in LEV group and 23 babies in PB group) 
were followed at 3 months, 6 months, and 12 months. Short- and 
long-term effect comparison between two groups is described 
in Table 2. After clinical control of seizures, EEG was done in 
54 babies out of which 49 (90.7%) had normal EEG record and 
5 (9.2%) had abnormal EEG records. There was no significant 
difference in incidence of abnormal EEG records in the two 
groups. The common abnormalities noted were electrical spikes 
and background abnormalities such as “burst suppression” pattern 
or low electrical voltage.
DISCUSSION
Our study demonstrated that LEV and PB, both were equally 
effective in the control of clinical seizures in term neonates 
irrespective of the etiology, but LEV is superior in terms of 
short-term adverse effect and long-term neurodevelopmental 
outcome than PB. The most common anticonvulsant used 
initially in neonates is PB [15]; although there are many concerns 
regarding the short-term as well as long-term adverse effects of 
PB. IV phenytoin and benzodiazepines are commonly employed 
as second-line IV medications in the treatment of NS [16]. In 
comparison, LEV is equally effective in controlling seizure and 
is safe due to its linear pharmacokinetics (half-life of 7 h), [17] 
rapid absorption (30 min), non-hepatic elimination, lack of 
protein binding (< 10%), and no known interactions with other 
anti-epileptic drugs [18].
Khan et al. studied 22 neonates on treatment with LEV and 
showed that seizures control in the majority (86%) of neonates 
was achieved by 1 h while all the patients were seizure-free by 
72 h. No significant side effects were reported by them [19]. 
Abend et al. retrospectively studied 23 neonates with seizures 
who received LEV and observed 50% seizure reduction within 
24 h. LEV was associated with >50% seizure reduction in 35% 
neonates, including seizure termination in 30% cases [20]. 
Shoemaker and Rotenberg reported seizure control with LEV. 
They did not report any adverse effects, and these babies remained 
seizure-free thereafter [21].
Ramantani et al. studied 38 neonates with seizures treated 
with LEV and reported that it is safe and effective in controlling 
NS [22]. Various studies have reported a wide range for LEV 
dosage ranging from 10 to 80 mg/kg/day [19-22]. Merhar 
et al. studied the pharmacokinetics of LEV in neonates and noted 
that neonates had lower plasma clearance, higher volume of 
distribution, and longer half-life as compared with older children 
and adults [23]. Falsaperla et al. conducted a study in 16 neonates 
with NS and used LEV as the lone drug and PB as adjunctive 
therapy and found it to be safe and effective first-line drug [24].
Maitre et al. compared 280 infants at 24 months corrected 
age and found that PB was associated with the worse 
neurodevelopmental outcomes than LEV [25]. Venkatesan 
et al. conducted a study on 127 neonates suffering from HIE and 
found LEV as an efficacious medication with no negative side 
effects [26]. It is one of the few studies done which compares the 
Table 1: Baseline characteristics of the study population
Parameters LEV group 
(n=42) (%)
PB group 
(n=38) (%)
Gestational age* (week) 38.6 (1.45) 38.9 (1.87)
Weight* (kg) 2.71 (0.4) 2.55 (0.05)
Male sex 28 (66.6) 29 (76.3)
Etiology of seizure
Hypoxic ischemic encephalopathy 23 (54.7) 20 (52.6)
Sepsis 18 (42.8) 16 (42.1)
Intracranial bleeding 1 (2.38) 2 (5.26)
Type of seizure
Subtle 21 (50.0) 20 (52.6)
Tonic 18 (42.8) 16 (42.1)
Clonic 3 (7.14) 2 (5.26)
In number (%), *mean standard deviation, PB: Phenobarbitone, LEV: Levetiracetam
Table 2: Short- and long-term effect comparison between two 
groups
Outcome LEV 
group
PB 
group
p-value
Short-term adverse effects
Respiratory depression 1 (n=42) 7 (n=38) 0.024
Sedation 1 (n=42) 6 (n=38) 0.049
Hypotension 1 (n=42) 7 (n=38) 0.024
Long-term outcome at 12 months
Neuromotor developmental delay 2 (n=25) 8 (n=23) 0.033
Mental retardation 1 (n=25) 6 (n=23) 0.044
Comorbidities 1 (n=25) 6 (n=23) 0.044
PB: Phenobarbitone, LEV: Levetiracetam
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effects of LEV with PB in NSs. However, double-blind prospective 
controlled studies and long-term evaluation of cognitive outcome 
is called for, to establish it as a reasonable alternative to PB. Lack 
of blinding of clinical outcomes, inability to monitor serum drug 
level and cerebral function, small sample size, and unavailability 
of bedside EEG were the limitation of our study.
CONCLUSION
The results obtained in our study illustrate the efficacy and 
safety of LEV as the first-line treatment in NSs. Our study 
demonstrated that LEV and PB, both were equally effective 
in control of clinical seizures in term neonates irrespective of 
the etiology; however, LEV was superior in terms of short-
term adverse effects and long-term neurodevelopmental 
outcome than PB.
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